Denali Therapeutics (DNLI) Change in Account Payables (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Change in Account Payables data on file, last reported at $3.9 million in Q1 2026.

• On a quarterly basis, Change in Account Payables rose 246.84% year-over-year to $3.9 million in Q1 2026; TTM through Mar 2026 was -$1.0 million, a 45.24% increase from a year earlier, with the FY2025 full-year figure at -$7.5 million, down 623.31% from the prior year.
• Change in Account Payables for Q1 2026 stood at $3.9 million, up from -$3.4 million in the prior quarter.
• Over the last five years, Change in Account Payables for DNLI reached as high as $4.8 million in Q2 2023 and fell as low as -$4.4 million in Q3 2024.
• Historically, Change in Account Payables has averaged $146882.4 across 5 years, with a median of $839000.0 in 2022.
• Across the five-year window, Change in Account Payables plunged 2098.72% in 2022 and jumped 469.01% in 2023, its largest moves.
• Year by year, Change in Account Payables stood at -$1.7 million in 2022, then dropped by 21.34% to -$2.1 million in 2023, then soared by 161.8% to $1.3 million in 2024, then tumbled by 365.01% to -$3.4 million in 2025, then soared by 213.7% to $3.9 million in 2026.
• Per Business Quant data, the three most recent Change in Account Payables figures were $3.9 million in Q1 2026, -$3.4 million in Q4 2025, and -$4.1 million in Q3 2025.